Deep Learning-Driven Multimodal Fusion Model for Prediction of Middle Cerebral Artery Aneurysm Rupture Risk.

RATIONALE AND

OBJECTIVES

The decision to treat unruptured intracranial aneurysms remains a clinical dilemma. Middle cerebral artery (MCA) aneurysms represent a prevalent subtype of intracranial aneurysms. This study aims to develop a multimodal fusion deep learning model for stratifying rupture risk in MCA aneurysms.

MATERIALS AND

METHODS

We retrospectively enrolled internal cohort and two external validation datasets with 578 and 51 MCA aneurysms, respectively. Multivariate logistic regression analysis was performed to identify independent predictors of rupture. Aneurysm morphological parameters were quantified using reconstructed CT angiography (CTA) images. Radiomics features of aneurysms were extracted through computational analysis. We developed MCANet - a multimodal data-driven classification model integrating raw CTA images, radiomics features, clinical parameters, and morphological characteristics - to establish an aneurysm rupture risk assessment framework. External validation was conducted using datasets from two independent medical centers to evaluate model generalizability and small-sample robustness. Four key metrics, including accuracy, F1-score, precision, and recall, were employed to assess model performance.

RESULTS

In the internal cohort, 369 aneurysms were ruptured. Independent predictors of rupture included: the presence of multiple aneurysms, aneurysm location, aneurysm angle, presence of daughter-sac aneurysm, and height-width ratio. MCANet demonstrated satisfactory predictive performance with 91.38% accuracy, 96.33% sensitivity, 90.52% precision, and 93.33% F1-score. External validation maintained good discriminative ability across both independent cohorts.

CONCLUSION

The MCANet model effectively integrates multimodal heterogeneous data for MCA aneurysm rupture risk prediction, demonstrating clinical applicability even in data-constrained scenarios. This model shows potential to optimize therapeutic decision-making and mitigate patient anxiety through individualized risk assessment.